Skip to content

Dicerna Pharmaceuticals Inc

Delisted

CIK 1399529fmd_1EEM50ZH85XEVM1HST6GKJ43WBManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Sep 30, 2021, 36 periods

Latest annual · FY2020

Millions
Total revenues
164
Operating income
(113)
Net income
(113)
Free cash flow
163

Latest quarter · Q3 FY2021

Millions
Total revenues
63
Operating income
(20)
Net income
(17)
Free cash flow
(64)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2017 to FY2020
+442.3%
Revenue, 5 yearsFY2015 to FY2020
+289.2%
Net income, 5 yearsFY2015 to FY2020
n/m

Dicerna Pharmaceuticals Inc financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2020FY2019ChangeSource
Revenue$164.3 million$23.9 million+587.4%10-K 2021-02-26 · proof
Operating income-$113.2 million-$128.2 million10-K 2021-02-26 · proof
Net income-$112.7 million-$120.5 million10-K 2021-02-26 · proof
Cash from operating activities$175.1 million-$692,00010-K 2021-02-26 · proof
Free cash flow$163.4 million-$7 million10-K 2021-02-26 · proof
Total assets$707.8 million$597.4 million+18.5%10-K 2021-02-26 · proof
Total liabilities$570.1 million$445.2 million+28%10-K 2021-02-26 · proof
Cash and cash equivalents$126 million$152.8 million-17.5%10-K 2021-02-26 · proof
What was Dicerna Pharmaceuticals Inc's revenue in fiscal 2020?
Dicerna Pharmaceuticals Inc reported revenue of $164.3 million for fiscal 2020 (the year ended Dec 31, 2020), against $23.9 million the year before (+587.4%). Source: the 10-K filed with the SEC on Feb 26, 2021. SEC
What was Dicerna Pharmaceuticals Inc's operating income in fiscal 2020?
Dicerna Pharmaceuticals Inc reported operating income of -$113.2 million for fiscal 2020 (the year ended Dec 31, 2020), against -$128.2 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2021. SEC
What was Dicerna Pharmaceuticals Inc's net income in fiscal 2020?
Dicerna Pharmaceuticals Inc reported net income of -$112.7 million for fiscal 2020 (the year ended Dec 31, 2020), against -$120.5 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2021. SEC
What was Dicerna Pharmaceuticals Inc's cash from operating activities in fiscal 2020?
Dicerna Pharmaceuticals Inc reported cash from operating activities of $175.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$692,000 the year before. Source: the 10-K filed with the SEC on Feb 26, 2021. SEC
What was Dicerna Pharmaceuticals Inc's free cash flow in fiscal 2020?
Dicerna Pharmaceuticals Inc reported free cash flow of $163.4 million for fiscal 2020 (the year ended Dec 31, 2020), against -$7 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2021. SEC
What are Dicerna Pharmaceuticals Inc's total assets?
As of Dec 31, 2020, Dicerna Pharmaceuticals Inc reported total assets of $707.8 million, against $597.4 million a year earlier (+18.5%). Source: the 10-K filed with the SEC on Feb 26, 2021. SEC
What are Dicerna Pharmaceuticals Inc's total liabilities?
As of Dec 31, 2020, Dicerna Pharmaceuticals Inc reported total liabilities of $570.1 million, against $445.2 million a year earlier (+28%). Source: the 10-K filed with the SEC on Feb 26, 2021. SEC
What are Dicerna Pharmaceuticals Inc's cash and cash equivalents?
As of Dec 31, 2020, Dicerna Pharmaceuticals Inc reported cash and cash equivalents of $126 million, against $152.8 million a year earlier (-17.5%). Source: the 10-K filed with the SEC on Feb 26, 2021. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1399529&period_type=annual&limit=5"

Information only, not investment advice.